Multiple sclerosis biotech firm TG Therapeutics is Thursday's pick for IBD 50 Growth Stocks To Watch. TGTX stock jumped Thursday and broke out of an irregular base and is in a buy zone.
Shares of TG Therapeutics bolted higher after the company topped fourth-quarter sales expectations with in-line earnings Monday.
The IBD 50 and IBD Leaderboard component makes a multiple sclerosis treatment named Briumvi, which is sold in the U.S. and Europe. The treatment is specifically used for a form of relapsing multiple sclerosis.
The treatment's main competitors are Roche's Ocrevus and Novartis' Kesimpta.
TG Therapeutics ranks No. 9 out of 728 stocks in the Medical-Biomed/Biotech group, which holds the 74th spot out of the 197 industry groups Investor's Business Daily tracks.
The stock was the biggest gainer on the IBD 50 Thursday.
Investor's Corner: What Is Average True Range
TGTX Stock Break Out Of A Base
TG Therapeutics stock rebounded more than 6% Thursday in heavier-than-average volume after pulling back Wednesday. On Thursday's jump, shares broke out of a consolidation with a 36.84 buy point and are in a buy zone up to 38.68.
The move follows a 14.4% pop in heavy trading Monday following the earnings release. The biotech stock burst through its 50-day moving average on Monday's leap. This is the stock's second attempt this week at breaking out, as it tapped the buy point Tuesday, but the breakout faded.
Investors should be cautious of breakouts in the current market weakness. Investor's Business Daily's The Big Picture offers current market analysis.
TG Therapeutics' relative strength line increased sharply after the earnings report and reached a 52-week high as shown by the blue dot on its weekly MarketSurge chart.
In addition, the stock holds a 97 IBD Relative Strength Rating. Shares have climbed nearly 24% so far this year.
Multiple Sclerosis Treatment Sales Soar
The biotech company's fourth-quarter Briumvi sales grew to $103.6 million. Further, its 2024 net U.S. sales of Briumvi grew around 250%, according to the company's earnings release.
TG Therapeutics gave a full-year 2025 revenue outlook for its Briumvi treatment of $540 million vs. forecasts for $534.4 million.
Full-year 2025 profit estimates show earnings of 99 cents a share, up from 15 cents in 2024. And 2025 estimates call for a 95% increase in earnings to $1.93 a share.
Its IBD Accumulation/Distribution Rating of A- indicates fairly heavy institutional buying over the last 13 weeks. And its up/down volume ratio of 1.3 shows positive demand for TGTX stock over the last 50 days.
The biotech stock's mutual fund ownership has increased for five straight quarters, according to Leaderboard data.
Lastly, it holds a Composite Rating of 94.
Follow Kimberley Koenig for more stock market news on X, the platform formerly known as Twitter, @IBD_KKoenig.
